126 related articles for article (PubMed ID: 35128935)
1. Cutaneous Squamous Cell Carcinoma Subjected to Anti PD-1 Immunotherapy: Monitoring Response Through Serial PET/CT Scans with
Filippi L; Proietti I; Petrozza V; Bagni O; Schillaci O
Cancer Biother Radiopharm; 2022 Apr; 37(3):226-232. PubMed ID: 35128935
[No Abstract] [Full Text] [Related]
2. The Prognostic Role of [
Filippi L; Proietti I; Petrozza V; Potenza C; Bagni O; Schillaci O
Cancer Biother Radiopharm; 2024 Feb; 39(1):46-54. PubMed ID: 37883658
[No Abstract] [Full Text] [Related]
3. FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma.
McLean LS; Cavanagh K; Hicks RJ; Callahan J; Xie J; Cardin A; Lim AM; Rischin D
Cancer Imaging; 2021 Oct; 21(1):57. PubMed ID: 34645517
[TBL] [Abstract][Full Text] [Related]
4. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST.
Goldfarb L; Duchemann B; Chouahnia K; Zelek L; Soussan M
EJNMMI Res; 2019 Jan; 9(1):8. PubMed ID: 30694399
[TBL] [Abstract][Full Text] [Related]
5. Restaging [
Mahajan S; Barker CA; Mauguen A; Singh B; Pandit-Taskar N
J Am Acad Dermatol; 2020 Apr; 82(4):878-886. PubMed ID: 31562942
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of 18F-FDG-PET/CT in staging cutaneous squamous cell carcinoma.
Mahajan S; Barker CA; Singh B; Pandit-Taskar N
Nucl Med Commun; 2019 Jul; 40(7):744-751. PubMed ID: 31095044
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of [
Sachpekidis C; Weru V; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2699-2714. PubMed ID: 37099131
[TBL] [Abstract][Full Text] [Related]
8. The role of interim
Sachpekidis C; Anwar H; Winkler J; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1289-1296. PubMed ID: 29478079
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.
Sachpekidis C; Kopp-Schneider A; Hakim-Meibodi L; Dimitrakopoulou-Strauss A; Hassel JC
Melanoma Res; 2019 Apr; 29(2):178-186. PubMed ID: 30653029
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
[No Abstract] [Full Text] [Related]
11. The Value of
Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
13. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
Wachsmann JW; Ganti R; Peng F
Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
[TBL] [Abstract][Full Text] [Related]
14. Assessment of early metabolic progression in melanoma patients under immunotherapy: an
Sachpekidis C; Kopp-Schneider A; Hassel JC; Dimitrakopoulou-Strauss A
EJNMMI Res; 2021 Sep; 11(1):89. PubMed ID: 34495433
[TBL] [Abstract][Full Text] [Related]
15. Assessment of perineural spread in advanced cutaneous squamous cell carcinomas treated with immunotherapy.
Cavanagh K; McLean LS; Lim AM; Cardin A; Levy SM; Rischin D
Cancer Imaging; 2024 Mar; 24(1):37. PubMed ID: 38500235
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal studies of the
Sachpekidis C; Anwar H; Winkler JK; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Cancer Immunol Immunother; 2018 Aug; 67(8):1261-1270. PubMed ID: 29872898
[TBL] [Abstract][Full Text] [Related]
17. Use of Diffusion-Weighted Imaging and
Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
[TBL] [Abstract][Full Text] [Related]
18. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
19. [
Filippi L; Proietti I; Petrozza V; Aversa S; Fiorentino F; Potenza C; Bagni O; Schillaci O; Cantonetti M
Cancer Biother Radiopharm; 2023 May; 38(4):268-272. PubMed ID: 36706264
[TBL] [Abstract][Full Text] [Related]
20. 3'-Deoxy-3'-
Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
